Opus Genetics is trading 5.29% down at $3.58 after reporting second-quarter 2026 results before the August 6, 2026 session, as revenue fell to $0.8 million from $2.9 million.
- R&D expenses increased to $11.2 million, while net loss reached $8.1 million.
- The company reported $88.8 million in cash and runway through 2029, alongside upcoming clinical milestones.